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Abstract The amount of a-tocopherol (a-TOH) can dramati-
cally alter the extent of radical-induced oxidation of low density 
lipoprotein (LDL) lipids, a process generally thought to be 
important in atherogenesis. However, LDL with atherogenic 
features can also be formed in vitro by exposure to the strong 
non-radical oxidant hypochlorite (HOC1), which preferentially 
oxidises LDL apolipoprotein B-100. Here we show that varying 
LDL content of a -TOH by vitamin supplementation or depletion 
has no effect on the extent of HOCl-induced oxidation of 
apolipoprotein B-100 as measured by the loss of lysine and 
tryptophan residues, and the alteration in relative electrophoretic 
mobility of the lipoprotein particle. 
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1. Introduction 
Oxidation of low-density lipoprotein (LDL) is thought to 
be an important early event in atherogenesis [1] and may be 
modulated by the content of antioxidants within and sur-
rounding LDL. Indeed, lipophilic antioxidants that associate 
with L D L are of interest as potential therapeutic agents [2]. 
However, despite some recent promising results [3], prospec-
tive randomised trials on the effect of supplementation with oc-
tocopherol ( a -TOH, quantitatively the major lipid-soluble 
antioxidant in L D L extracts) on cardiovascular outcome in 
humans have overall been disappointing [4]. 
There is convincing evidence that L D L or LDL-like par-
ticles isolated from human atherosclerotic lesions are oxida-
tively modified, both in lipid and in protein moieties. While 
the precise nature of the oxidant(s) active in vivo remains 
uncertain, recent evidence suggests that hypochlorite (HOC1) 
could be involved. Thus, both active myeloperoxidase [5] and 
HOCl-oxidised proteins [6] have been identified in human 
atherosclerotic lesions, and HOC1 can convert L D L into an 
atherogenic form in vitro [7,8]. HOCl-induced oxidation of 
L D L differs from at least some radical-mediated oxidation 
(e.g. copper-induced oxidation) in that the strong nucleophilic 
oxidant HOC1 preferentially oxidises the protein moiety of 
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Abbreviations: AAPH, 2,2'-azobis(2-amidinopropane) hydrochloride; 
apo B-100, apolipoprotein B-100; CE-0(0)H, the sum of cholesteryl 
ester hydroperoxides and cholesteryl ester hydroxides; DMSO, 
dimethyl sulphoxide; EDTA, ethylenediamine tetraacetic acid; HOC1, 
an equilibrium mixture of hypochlorous acid and hypochlorite at pH 
7.4; LDL, low-density lipoprotein; REM, relative electrophoretic 
mobility; a-TOH, a-tocopherol 
L D L rather than the lipid moieties or lipophilic antioxidants 
[7-10]. Wha t is not known to date is whether a - T O H can 
affect HOCl-induced L D L and protein modification. Clarifi-
cation of this could have implications for the design of anti-
atherogenic drugs based on antioxidant activity. We therefore 
tested the effect of supplementation with, and depletion of, a-
T O H on the extent of HOCl-mediated oxidation of LDL. 
2. Materials and methods 
Nanopure water was used for all buffers and aqueous solutions, 
which were subsequently treated with Chelex-100 (Bio-Rad, Hercules, 
CA, USA) to remove contaminating transition metals. Heparinised 
vacutainers were obtained from Becton-Dickinson (Lincoln Park, 
NJ, USA); bicinchoninic acid assay reagents, reduced glutathione 
and fluorescamine from Sigma Diagnostics (Castle Hill, NSW, Aus-
tralia); a-TOH from Henkel (Sydney, Australia) and reagent HOC1 
(5% available chlorine minimum) from Aldrich (Castle Hill, NSW, 
Australia). The concentration of HOC1 was determined spectrophoto-
metrically at pH 13.0 using e292nm = 350 M _ 1 cm - 1 [11]. 2,2'-Azo-
bis(2-amidinopropane) hydrochloride (AAPH) was purchased from 
Polysciences (Warrington, PA, USA). Ebselen (2-phenyl-1,2-benzoiso-
selenazol) was a generous gift from Daiichi Pharmaceuticals (Tokyo, 
Japan). Phosphate-buffered saline (PBS) contained 150 mM NaCl and 
50 mM (Na2H and NaH2)P04 at pH 7.4 and was used for gel filtra-
tion and resuspension of LDL after its isolation. For LDL isolation, 
0.1% (w:v) ethylenediamine tetraacetic acid (EDTA) was added to the 
PBS. Organic solvents were of HPLC quality (EM Science, Gibbs-
town, NJ, USA) or the highest grade available. Hexane was washed 
with nanopure water prior to its use. Collection of blood for this work 
was approved by the local human ethics committee. 
2.1. LDL preparation 
Fresh blood was obtained from non-fasted, healthy male or female 
subjects (20-40 years old) and drawn into heparin vacutainers. The 
blood was centrifuged at 4°C (lOOOXg for 15 min) to separate cells 
from plasma. LDL was isolated from plasma by ultracentrifugation 
by a rapid analytical method (417000Xg, 2 h, 15°C) using 5.1 ml 
tubes and a TL100.4 rotor [12]. All subsequent handling of the sam-
ples was carried out at 4°C. Low molecular weight compounds were 
removed by gel filtration through a PD-10 column (Pharmacia, Upp-
sala, Sweden), and the LDL resuspended in PBS. For supplementa-
tion and replenishment procedures (see below), lipoprotein-depleted 
plasma was obtained by removing 1.7 ml of the bottom fraction of the 
plasma following its density ultracentrifugation described above. 
2.2. Supplementation, depletion or replenishment of a-TOH in LDL 
Freshly isolated LDL was depleted of a-TOH by rapid oxidation 
with AAPH at 37°C [10]. The reaction was stopped by cooling to 4°C 
upon approx. 90% TOH depletion (as assessed by HPLC analysis; see 
below) and the AAPH removed by gel filtration. This method con-
sumes a-TOH with little lipid peroxidation [10] and no significant loss 
of amino acid residues (see Section 3). Any small amounts of lipid 
hydroperoxides that formed were reduced to the nonreactive hydrox-
ides by treatment of the LDL with ebselen and reduced glutathione, 
followed by gel filtration [13]. LDL referred to as 'native' or 'supple-
mented' was treated similarly with the exception that AAPH was 
replaced with PBS for the 37°C incubation. 
Subsequently, native LDL and depleted LDL were supplemented 
and replenished with a-TOH, respectively, by incubation in lipopro-
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tein-deficient plasma (2:1, v:v) with 20 mM cc-TOH in DMSO [10] at 
37°C for 4 h [14]. In addition, aliquots of native LDL and depleted 
LDL were incubated with lipoprotein-deficient plasma treated with 
DMSO alone under the same conditions as those used for supplemen-
tation. The final concentration of DMSO in all samples was 3% (v:v). 
Following supplementation or replenishment, LDL was reisolated by 
ultracentrifugation as described for native LDL and then gel-filtered. 
Replenished LDL, with oc-TOH at a comparable concentration to that 
found in native LDL, has been shown to behave similarly to native 
LDL upon oxidation with a range of different oxidants under mild 
oxidising conditions [10], indicating that the above in vitro manipu-
lations do not affect LDL oxidisability. LDL was oxidised with HOCl 
within 2 days of collection of fresh blood. The concentration of LDL 
in the resulting solutions was standardised using the bicinchoninic 
acid assay [15]. The protocol described in the manufacturer's instruc-
tions was modified by the addition of SDS [16]; bovine serum albu-
min (Sigma Diagnostics) was used as a standard. 
2.3. HOCl-mediated oxidation of LDL 
Oxidation of LDL with reagent HOCl was carried out on ice by the 
addition of 1 vol of HOCl, freshly diluted in PBS, to 4 vol of LDL 
solution (0.08-0.4 μΜ, final apo B-100 concentration). After addition 
of HOCl, the reaction mixture was mixed briefly ( < 1 s) and left on 
ice for 15 min. 
2.4. Quantification of amino acid residues 
Unmodified lysine residues in LDL were quantified by fluoresc-
amine fluorescence (excitation 390 nm, emission 475 nm) using the 
manual procedure of Bohlen [17] described in [7]. Tryptophan fluo-
rescence of LDL was measured (in the absence of SDS) using excita-
tion 280 nm and emission 335 nm [18]. For both lysine and trypto-
phan residues, the fluorescence of HOCl-oxidised samples was 
expressed as a percentage of the fluorescence of the corresponding 
LDL sample not treated with HOCl. 
2.5. Agarose gel electrophoresis 
LDL ( ~ 1 ^g protein) was loaded on pre-cast agarose gels (Ciba 
Corning) and the gels run in barbitone buffer (pH 8.6) at 90 V for 45 
min. Following electrophoresis, the gels were fixed in methanol for 30 
s, dried at 50°C for 15 min, stained with Fat Red 7B stain, destained 
in 70% (v/v) methanol and dried overnight at room temperature. 
2.6. Measurement of antioxidants and lipid content of LDL 
To determine the content of LDL antioxidants, unoxidised lipids 
and hydroperoxides and hydroxides of cholesteryl esters (the latter 
two collectively referred to as CEO(O)H), a 100 μΐ aliquot of the 
reaction mixture was extracted with 1 ml of cold methanol containing 
0.02% (v:v) acetic acid and 5 ml hexane. The vacuum-dried hexane 
phase was redissolved in propan-2-ol for analysis. Cholesterol, choles-
teryl esters and CE-0(0)H were separated by HPLC and quantified 
by ultraviolet detection as described [12]. a-TOH was determined by 
HPLC with electrochemical detection [12]. Lipids and a-TOH were 
internally standardised to cholesterol, the content of which changed 
only marginally in the different LDL samples as a result of treatment 
with HOCl (mean percent loss ± S.D. at 600 molecules of HOCl per 
LDL was 5.6 ±4.5). 
3. Results 
The a-TOH contents of the differently treated LDL samples 
varied up to 100-fold (Table 1). CE-0(0)H were barely de-
tectable in native and supplemented LDL, and < 10 mole-
cules were present per particle in depleted and replenished 
LDL (Table 1). The concentration of cholesteryl linoleate 
(Table 1) and cholesteryl arachidonate (not shown), the two 
major cholesteryl esters in LDL, was not significantly different 
in the various samples. Similarly, neither LDL's lysine and 
tryptophan residues nor its relative electrophoretic mobility 
(REM) were significantly different between native and treated 
samples (Table 1). 
Upon exposure of these various LDL samples to reagent 
HOCl, lysine and tryptophan residues were lost in a concen-
tration dependent manner, to an extent independent of the 
amount of a-TOH present in the LDL (Fig. 1A,B). Oxidation 
of lysine and tryptophan residues together accounts for 
~ 75% of the HOCl added to LDL [7], which makes these 
reactions quantitatively important. The concentration of a-
TOH in the lipoprotein particle did not influence the HOC1-
induced increase in the REM of LDL (Fig. 2). A substantial 
increase in REM, together with modification of the lysine 
amino group, are indicative of conversion of LDL into a 
particle recognised by the scavenger receptor [19] and hence 
denote the potential of the modified lipoprotein particle to be 
atherogenic by causing lipid accumulation in macrophages. 
As expected [7], treatment with HOCl resulted in a small 
and concentration-dependent decrease in the mean values of 
a-TOH in native LDL (Table 2). Likewise, a-TOH-supple-
mented, -replenished and -depleted LDL showed a small ex-
tent of oxidation of the vitamin (Table 2). However, even with 
the highest initial a-TOH concentration the extent of vitamin 
E consumption corresponded to less than 3% of the HOCl 
added, assuming a 1:1 stoichiometry. Supplemented and re-
plenished LDL had a larger absolute loss of a-TOH than 
native LDL (Table 2). However, when measured as a propor-
tion of the initial amount of a-TOH present, the extent of 
vitamin oxidation in these samples was less than that in native 
LDL (not shown). Conversely, depleted LDL (which gave rise 
to a smaller absolute loss of a-TOH than native LDL, Table 
2) showed an increased proportional loss of the vitamin com-
pared with native LDL (not shown). These results indicate 
that LDL's a-TOH is not a preferred substrate for reagent 
HOCl. 
Exposure of LDL to HOCl resulted in minimal formation 
Table 1 
Comparison of native, α-TOH-supplemented, -depleted and -replenished LDL prior to HOCl oxidation 
Treatment of LDL 
Native Supplemented Depleted Replenished 
oc-TOHa 
CE-OiO)Hab 
Chl8:2b 
Lysineb 
Tryptophanb 
REMb 
7.68 ±3.04 
(5.68-11.2) 
0.09 ±0.08 
1.00 ±0.00 
1.00 ±0.00 
1.00 ±0.00 
1.00 ±0.00 
59.5 ±34.1 
(39.6-98.9) 
0.36 ±0.21 
1.04 ±0.06 
1.03 ±0.09 
1.16±0.25 
1.06 ±0.01 
1.41 ±0.85 
(0.81-2.38) 
9.20 ±1.26 
0.98 ±0.03 
0.93 ±0.07 
0.85±0.17 
1.03±0.11 
43.9 ±30.1 
(22.9-78.3) 
9.70 ±1.34 
1.03 ±0.03 
0.93 ±0.14 
0.98 ±0.10 
1.10±0.10 
The values show mean ± S.D. of three independent experiments using LDL isolated from blood of three different donors. CE-0(0)H, cholesteryl 
ester hydro(pero)xides; Chi8:2, cholesteryl linoleate; REM, relative electrophoretic mobility. 
aUnits used are number per LDL particle or equivalently mole per mole LDL. The range is given in parentheses. 
bFraction of that detected in native LDL. 
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Fig. 1. HOCl-induced loss of lysine residues (A) and tryptophan flu-
orescence (B) of apo B-100 is independent of the amount of a-TOH 
in LDL. Native LDL (open circles), LDL supplemented with a-
TOH (filled circles), LDL depleted of a-TOH (filled squares) and 
depleted LDL replenished with a-TOH (filled triangles) were oxi-
dised with reagent HOCl at 4°C for 15 min. The remaining lysine 
and tryptophan residues were assayed by the fluorescamine assay 
and fluorescence (excitation 280 nm, emission 335 nm), respectively. 
The results shown represent the mean ± S.D. from three independent 
experiments with LDL isolated from three separate donors. 
of CE-0(0)H, and the extent of this was indistinguishable for 
the various LDL samples. Thus, 0.21 ±0.21, 0.41 ±0.34, 
0.08 ±0.25, and 0.93 ±0.59 molecules of CE-0(0)H were 
formed per native, α-TOH-supplemented, -depleted, and -re-
plenished LDL particle, respectively as a result of exposure to 
600 molecules HOCl per lipoprotein particle. These results are 
comparable with our previous findings [7]. Also, independent 
of the content of a-TOH, exposure of LDL to HOCl did not 
result in detectable loss of cholesteryl esters (not shown). 
4. Discussion 
The methods used in this study to prepare LDL with var-
ious amounts of a-TOH had minimal effect on the protein 
and lipid components of the lipoprotein particle (Table 1), 
and this allowed the examination of the role of a-TOH in 
HOCl-induced oxidation of LDL. We found that neither the 
extent of oxidation of lysine and tryptophan residues nor the 
changes in REM of LDL correlated with the a-TOH concen-
tration of the lipoprotein. In addition, even at low concentra-
tions of HOCl, there was no dramatic inhibition of protein 
oxidation which could correspond to a timeline 'lag' phase. 
The lack of effect of a-TOH on HOCl-induced oxidative mod-
ification of LDL apo B-100 is in contrast to the conspicuous 
effect of the vitamin when lipid peroxidation in LDL is in-
duced by radical oxidants. Using initially peroxide-free LDL 
and either AAPH, Cu2+ or soybean lipoxygenase as the oxi-
dant under low radical flux conditions, depletion of a-TOH to 
an extent similar to that used in this study inhibited lipid 
peroxidation by > 80% [10]. Under conditions of high radical 
flux and highly reactive radical oxidants such as hydroxyl 
radicals, depletion of the vitamin from LDL increased the 
overall extent of lipid peroxidation [10]. In addition, under 
such strongly oxidising conditions, supplementation of LDL 
with a-TOH decreased the extent and delayed the onset of 
rapid lipid peroxidation [10,20,21]. Thus, independent of the 
oxidant flux, a-TOH controls radical-induced LDL lipid per-
oxidation. 
In contrast to this, a-TOH had little effect on HOCl-in-
duced LDL lipid peroxidation, as indicated by the lack of a 
large effect on both the formation of CE-0(0)H and the loss 
of cholesteryl esters. This is not surprising given that HOCl is 
expected to catalyse two-electron oxidation reactions rather 
than the one-electron reactions required for lipid peroxida-
tion. We have shown previously that the concentrations of 
HOCl used here ( < 3 mmole/g protein) do not directly oxidise 
substantial amounts of lipid in LDL; rather apo B-100 is the 
preferred target [7,8]. For this reason, the effect of a-TOH on 
radical-induced oxidation of apo B-100 would be more mean-
ingful for comparison. In this context, direct protein oxidation 
needs to be distinguished from that induced by secondary 
reactions derived from breakdown of lipid peroxides. 
As far as we are aware, there is no strong evidence that a-
TOH can substantially prevent direct oxidation of isolated 
proteins induced by one-electron oxidants. Dean and co-
workers showed that the water-soluble analogue of a-TOH, 
Trolox, efficiently inhibited AAPH-induced loss of tryptophan 
residues in isolated BSA [22]. However, methanolic solutions 
of a-TOH were without effect, and when a-TOH was added 
in soybean phosphatidylcholine liposomes, the inhibitory ef-
fect on tryptophan loss observed was not clearly distinguished 
from that of the vitamin-free liposomes [22]. a-TOH can, 
however, repair tyrosine phenoxy radicals in partially un-
folded lysozyme [23]. 
The situation becomes more complicated with biological 
protein-lipid mixtures. With regard to LDL, Giessauf et al. 
[24] reported that supplementing the lipoprotein with vitamin 
E had no effect on the initial rate of Cu2+-induced tryptophan 
Table 2 
Oxidation of a-TOH upon treatment of the various LDL samples with HOCl 
LDL HOC1/LDL particle 
0 
7.7 ±3.0 
60 ±34 
1.4 ±0.8 
44 ±30 
100 
7.2 ±3.5 
50 ±22 
1.2±0.8 
41 ±27 
200 
6.8 ±3.7 
51 ±25 
1.1 ±0.8 
41 ±25 
400 
5.7 ±1.4 
48 ±26 
0.8 ±0.6 
38 ±24 
600 
4.2 ±1.9 
4 ±26 
0.3 ±0.2 
36 ±24 
Native 
Supplemented 
Depleted 
Replenished 
The values shown are from three independent experiments and are expressed as the mean ± S.D. of a-TOH per LDL particle (mole/mole). 
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Fig. 2. a-TOH does not influence the HOCl-induced increase in 
REM of LDL. Symbols and oxidation conditions are the same as 
for Fig. 1. The REM was assessed by agarose gel electrophoresis. 
The results shown represent the mean ± S.D. from three independent 
experiments with LDL isolated from three separate donors. 
loss, even though a - T O H consumption occurred more rapidly 
than that of t ryptophan. Also, blocking the thiol groups of 
apo B-100 increases the rate of a - T O H loss induced by per-
oxyl radicals [25] and Cu 2 + [26], indicating that the thiol res-
idues compete with the vitamin for the initiating oxidants and/ 
or those derived from them. However, one cannot conclude 
from these results that the vitamin prevents direct oxidation of 
apo B's amino acids. 
a - T O H can clearly affect protein oxidation dependent on 
secondary lipid peroxidation products [22,27], by affecting the 
formation and/or degradation of lipid hydroperoxides. Gen-
erally speaking, this type of protein oxidation is at tenuated by 
a - T O H under conditions where the vitamin decreases lipid 
peroxidation (see e.g. [9]). By contrast, under conditions 
where vitamin E promotes lipid peroxidation (see above), pro-
tein oxidation may not necessarily be enhanced in parallel due 
to a - T O H inhibiting the breakdown of lipid hydroperoxides 
[28]. However, such inhibition of such secondary protein ox-
idation by a - T O H does not appear to be relevant for oxida-
tion of LDL by reagent HOC1, as under the conditions 
studied in this work neither lipid peroxidation nor the break-
down of lipid hydroperoxides are major reactions. 
HOCl-exposed L D L shows atherogenic characteristics [7,8], 
the production of which is not dependent on lipid peroxida-
tion. The results presented in this work show that a - T O H is 
unable to prevent at least some of the oxidative protein mod-
ifications that may lead to these characteristics. Our findings 
could help explain the lack of clearly positive results in inter-
vention studies using a - T O H to inhibit coronary heart disease 
in humans [3,4,29]. Our results also suggest that studies on 
antioxidants as potential antiatherogenic agents may need to 
consider inhibitors of HOCl-mediated protein damage rather 
than exclusively focusing on effective radical scavengers and/ 
or inhibitors of lipid peroxidation. 
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